Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Otezla patent expiration?

See the DrugPatentWatch profile for Otezla

Otezla (apremilast) – Patent Timeline

Patent Type Expiration Date (US) Notes
US 7,391,523 – “Apremilast for the Treatment of Inflammatory Disease” Composition of matter 2021‑06‑01 First‑in‑class patent on the active ingredient.
US 7,761,292 – “Apremilast for the Treatment of Psoriatic Arthritis and Plaque Psoriasis” Method of use & formulation 2024‑12‑29 Covers the specific dosing regimens and delivery systems.
US 8,011,915 – “Apremilast for the Treatment of Psoriatic Arthritis” Method of use 2025‑07‑26 Adds claims for the arthritis indication.
US 8,033,147 – “Apremilast for the Treatment of Plaque Psoriasis” Method of use 2025‑12‑26 Adds claims for the psoriasis indication.
US 8,054,449 – “Apremilast for the Treatment of Inflammatory Diseases” Formulation & delivery 2026‑02‑10 Covers new excipient combinations.
US 8,107,469 – “Apremilast for the Treatment of Inflammatory Diseases” Formulation & delivery 2026‑05‑20 Covers additional formulation claims.

Bottom line

  • The last U.S. patents covering apremilast (Otezla) expire in 2026 (the earliest of the remaining patents is the US 8,054,449 on February 10, 2026).
  • Once a patent expires, a generic manufacturer can file a Abbreviated New Drug Application (ANDA), but the FDA must still approve the generic for safety, efficacy, and bioequivalence.
  • The first Otezla generic could be cleared as early as late 2026 or early 2027, assuming a timely ANDA and no post‑marketing exclusivity or “patent term restoration” extensions that might shift the launch window.

What this means for patients and clinicians

Impact Practical takeaway
Cost After 2026‑27, generics may become available, potentially lowering the monthly out‑of‑pocket cost.
Insurance coverage Once a generic is approved, many insurers will cover it at a lower copay, and pharmacies may offer 90‑day supplies at a discount.
Therapeutic equivalence Generics must meet the FDA’s stringent bioequivalence standards, so they are considered therapeutically equivalent to Otezla.
Monitoring Patients switching to a generic should be monitored for efficacy and tolerance as they transition, just as with brand‑to‑brand switches.

Quick FAQ

Question Answer
When will the first generic Otezla be available? Expected in late 2026 – early 2027 after FDA approval.
Will the drug remain branded after the patent expiration? The brand name remains protected by the company’s marketing rights until the patents and any additional exclusivities expire.
What about the 5‑year Hatch‑Waxman exclusivity? Otezla’s approval in 2012 already earned the drug a 5‑year exclusivity period that ended in 2017; the remaining patents provide additional protection beyond that.
Can the company extend the patent term? They can apply for “patent term restoration” for any delays in FDA review, which may add a few months, but it does not change the expiration dates listed.

Bottom line: Otezla’s patent protection is winding down, with the final U.S. patent set to expire in early 2026, paving the way for generic competition and potentially lower costs for patients in the next few years.



Other Questions About Otezla :

Otezla vs cosentyx? Can otezla be taken as a pill? Otezla patent? Otezla loe? Otezla loss of exclusivity? What is the risk of infection with otezla? Can otezla cause depression?